Background
Methods
Study subjects and design
Treatment regimen
Toxicity assessment
Response criteria and monitoring
Correlative molecular studies
Statistics
Results
Patient characteristics
Patient characteristics | Number (%) |
---|---|
Total patients enrolled | 20 |
Selinexor 60 mg | 3 |
Selinexor 80 mg | 17 |
Female | 14 (70%) |
Median age (years, range) | 61 (44–76) |
Disease state on enrollment | |
Untreated AML | 12 (60%) |
Relapsed or refractory AMLa | 8 (40%) |
Initial AML diagnosis | |
De novo AML | 12 (60%) |
Secondary AML after MDS | 8 (40%) |
European LeukemiaNet genetic risk group | |
Favorable | 4 (20%) |
Intermediate I/II | 8 (40%) |
Adverse | 8 (40%) |
Acquired mutation status | |
FLT3 | 3 (15%) with ITD, 2 (10%) with TKD mutation |
CEBPA | 2 (10%) (one had bi-allelic mutation) |
NPM1 | 5 (25%) (3 with FLT3 mutation) |
Median number of prior regimens (R/R only)a | 2 (range, 1–3) |
Toxicity
Adverse events | Total, n (%) | Grades 1 and 2 | Grade 3 | Grade 4 | Grade 5 |
---|---|---|---|---|---|
Febrile neutropenia | 14 (70%) | 14 | |||
Diarrhea | 8 (40%) | 8 | |||
Anorexia | 6 (30%) | 6 | |||
Electrolyte abnormalities | 6 (30%) | 6 | |||
Bacteremia | 5 (25%) | 5 | |||
Cardiac toxicityb | 5 (25%) | 2 | 3 | ||
Nausea/vomiting | 5 (25%) | 4 | 1a | ||
Fatigue | 5 (25%) | 5 | |||
Pneumonia | 4 (20%) | 4 | |||
Alopecia | 4 (20%) | 4 | |||
Line-associated DVT | 3 (15%) | 3 | |||
Acute kidney injury | 3 (15%) | 3 | |||
Rash | 3 (15%) | 3 | |||
Mood disorders | 3 (15%) | 3 | |||
Clostridium difficile colitis | 2 (10%) | 2 | |||
Syncope/pre-syncope | 2 (10%) | 1 | 1 | ||
Upper respiratory infection | 2 (10%) | 2 | |||
Mucositis | 2 (10%) | 2 | |||
Transaminitis | 2 (10%) | 2 | |||
Psychosis | 2 (10%) | 2 | |||
Typhlitis | 1 (5%) | 1 | |||
Hypoxia | 1 (5%) | 1 | |||
Urinary tract infection | 1 (5%) | 1a | |||
Cerebellar toxicity | 1 (5%) | 1a | |||
Hemorrhagic stroke | 1 (5%) | 1a | |||
Cellulitis | 1 (5%) | 1a | |||
Endocarditis | 1 (5%) | 1a | |||
Total | 93 | 55 | 37 | 0 | 1 |
Adverse events occurring ≤ 5% not listed above: diverticulitis, edema, dysuria, musculoskeletal pain, vaginitis, plantar fasciitis, dry mouth, dysphagia, otitis externa, conjunctivitis, gingivitis, chest pain, hyperbilirubinemia, hypoalbuminemia, INR increased, peripheral neuropathy, and insomnia. |
Response
Response rates | Total | CR (%) | CRi (%) | PR (%) | TF (%) | ORR (%) |
---|---|---|---|---|---|---|
Dose | ||||||
60 mg | 3 (15%) | 1 (33%) | 0 | 0 | 2 (66%) | 1 (33%) |
80 mg | 17 (85%) | 9 (53%) | 3 (18%) | 1 (6%) | 4 (24%) | 13 (76%) |
Age | ||||||
Age ≤ 60a | 10 (50%) | 6 (60%) | 1 (10%) | 1 (10%) | 2 (20%) | 8 (80%) |
Age > 60b | 10 (50%) | 4 (40%) | 2 (20%) | 0 | 4 (40%) | 6 (60%) |
AML diagnosis | ||||||
Newly diagnosed | 12 (60%) | 7 (58%) | 3 (25%) | 1 (8%) | 1 (8%) | 11 (92%) |
Relapsed/refractory | 8 (40%) | 3 (38%) | 0 | 0 | 5 (63%) | 3 (38%) |
European LeukemiaNet risk group | ||||||
Favorable | 3 (15%) | 3 (100%) | 0 | 0 | 0 | 3 (100%) |
Intermediate I/II | 9 (45%) | 4 (44%) | 2 (22%) | 0 | 3 (33%) | 6 (67%) |
Adverse | 8 (40%) | 3 (38%) | 1 (13%) | 1 (13%) | 3 (38%) | 5 (63%) |
Total | 20 (100%) | 10 (50%) | 3 (15%) | 1 (5%) | 6 (30%) | 14 (70%) |